Genmab launches partnership with OpenAI for ‘AI Everywhere’

Genmab (GMAB) announced that it is pioneering next-generation antibody therapies to treat cancer and other serious diseases. Their mission is ambitious: to revolutionize patient care with transformative “knock-your-socks-off” antibody treatments. “Genmab’s ambition is to integrate AI into everything we do,” said Tahi Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. “We anticipated AI to contribute significantly to the quality of our science, decision making, and efficiency in bringing medicines to patients.” As a company that has recently tripled in size, Genmab wanted to use AI to address operational challenges-and develop new ways of working with vast amounts of complex scientific data, the company said. Just one month after ChatGPT Enterprise launched, Genmab rolled it out to 1,000 employees. Now, less than a year later, the company announced that it has launched “AI Everywhere” to give ChatGPT access to almost everyone at the company-more than 2,000 licenses. Genmab said it now has more than 100 custom GPTs that help with everything from drafting documents, summarizing scientific literature to simple and advanced analytics of data. “Our partnership with OpenAI not only highlights Genmab’s commitment to innovation, but also aims to unleash every colleague’s inner algorithmic leader to truly unlock large language model’s potential and discover increasingly novel and progressive ways of leveraging AI to improve, and at times, re-imagine their tasks,” said Hisham Hamadeh, SVP and Global Head of Data Sciences and AI at Genmab. TheFly notes that previous reports have said that Nvidia (NVDA), Apple (AAPL) and Microsoft (MSFT) have discussed joining a funding round for OpenAI.